(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.
Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...
The medicine, called trikafta, can treat cystic fibrosis patients who have at least one F508del mutation in the transmembrane conductance regulator gene or a mutation that is responsive to trikafta ...
CF often arises from mutations that make the cystic fibrosis transmembrane conductance regulator (CFTR) protein misfolding and malfunction, causing thick mucus to aggregate in the lungs while also ...
severity of pulmonary disease and genotype for cystic-fibrosis transmembrane conductance regulator were not. Although half of the patients with liver disease were treated with ursodeoxycholic acid ...
The medication is a CF transmembrane conductance regulator (CFTR) modulator therapy, made to correct the malfunctioning protein made by the CFTR gene. Cystic Fibrosis Canada (CFC) is celebrating ...
The CFTR Protein Distribution Core offers high-quality, full-length recombinant cystic fibrosis transmembrane conductance regulator (CFTR) proteins expressed in and purified from mammalian cells. Wild ...
The initiative, conducted in collaboration with Intellia Therapeutics, aims to develop new treatments for cystic fibrosis ... cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
CF is caused by a mutation in the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). This gene is required to regulate the components of sweat, digestive juices ...